重症监护后综合征可能是实体瘤 (ST) 患者在 ICU 住院后无法接受适当癌症治疗的原因。我们的目的是确定与癌症治疗恢复相关的因素以及癌症治疗对 ICU 住院后 ST 患者转归的影响。我们进行了一项回顾性研究，纳入了 2014 年至 2019 年法国一项研究中入住 ICU 的所有 ST 患者。大学附属医院。共纳入患者219例。入住 ICU 时 SAPS II 中位数为 44.0 [IQR 32.8, 66.3]。在 ICU 住院后幸存的 136 名患者中，81 名（59.6%）在 ICU 出院后接受了癌症治疗。入住 ICU 后，体能状态 (PS) 为 3 或 4 级的患者显着增加（入院时为 16.2%，存活患者为 44.5%），而入住 ICU 后 PS 显着下降（中位差 - 1.5， 95% 置信区间 [-1.5-1.0], p < 0.001)。入住 ICU 前后的 PS 差异 (delta PS) 与无法接受癌症治疗（比值比 OR 0.34，95%CI 0.18-0.56，p 值 < 0.001）以及以下患者的 1 年死亡率独立相关：出院时存活于 ICU（风险比 HR 1.76，95%CI 1.34-2.31，p 值 < 0.001）。入住 ICU 之前的 PS（OR 3.73，95%IC 2.01-7.82，p 值 < 0.001）和住院时间（OR 1.23，95%CI 1.06-1.49，p 值 0.018）与 ICU 入住后较差的 PS 独立相关。出 ICU 时的 1 年和 3 年生存率分别为 62.3% (n = 136)、27.3% (n = 59) 和 17.1% (n = 37)。入住 ICU 后恢复癌症治疗的患者的中位生存期为 771 天 (95% CI 376-1058)，而未恢复治疗的患者的中位生存期为 29 天 (95% CI 15-49) (p< 0.001)。入住 ICU 之前和之后的 PS 是 ICU 入住后癌症治疗恢复和生存的关键决定因素。通过多学科干预来改善这些患者在 ICU 内和入住 ICU 后的一般状况，可能会改善癌症治疗的机会和长期生存。© 2024。作者。

Post-intensive care syndrome could be responsible for inability to receive proper cancer treatment after ICU stay in patients with solid tumors (ST). Our purpose was to determine the factors associated with cancer treatment resumption and the impact of cancer treatment on the outcome of patients with ST after ICU stay.We conducted a retrospective study including all patients with ST admitted to the ICU between 2014 and 2019 in a French University-affiliated Hospital.A total of 219 patients were included. Median SAPS II at ICU admission was 44.0 [IQR 32.8, 66.3]. Among the 136 patients who survived the ICU stay, 81 (59.6%) received cancer treatment after ICU discharge. There was an important increase in patients with poor performance status (PS) of 3 or 4 after ICU stay (16.2% at admission vs. 44.5% of patients who survived), with significant PS decline following the ICU stay (median difference - 1.5, 95% confidence interval [-1.5-1.0], p < 0.001). The difference between the PS after and before ICU stay (delta PS) was independently associated with inability to receive cancer treatment (Odds ratio OR 0.34, 95%CI 0.18-0.56, p value < 0.001) and with 1-year mortality in patients who survived at ICU discharge (Hazard ratio HR 1.76, 95%CI 1.34-2.31, p value < 0.001). PS before ICU stay (OR 3.73, 95%IC 2.01-7.82, p value < 0.001) and length of stay (OR 1.23, 95%CI 1.06-1.49, p value 0.018) were independently associated with poor PS after ICU stay. Survival rates at ICU discharge, at 1 and 3 years were 62.3% (n = 136), 27.3% (n = 59) and 17.1% (n = 37), respectively. The median survival for patients who resumed cancer treatment after ICU stay was 771 days (95%CI 376-1058), compared to 29 days (95%CI 15-49) for those who did not resume treatment (p < 0.001).Delta PS, before and after ICU stay, stands out as a critical determinant of cancer treatment resumption and survival after ICU stay. Multidisciplinary intervention to improve the general condition of these patients, in ICU and after ICU stay, may improve access to cancer treatment and long-term survival.© 2024. The Author(s).